Clinical Trial Update: Risperidone Augmentation for PTSD [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial from Duke University evaluated risperidone augmentation for post-traumatic stress disorder and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• Risperdal (risperidone)

Snippet

Sponsor: Duke University | Conditions: Post-Traumatic Stress Disorder | Phase 2, Phase 3 | Status: COMPLETED